When tracking the biotechnology sector, particularly firms focused on specialized hematological res Mar 2, 2026 — The share price of Oncopeptides AB (publ) as of 2 March 2026 is 1,62 kr / share. The market cap (or net worth) of Oncopeptides AB (publ) as of 2 earch, understanding the market dynamics of Oncopeptides AB TR is essential for any observer of the Nordic markets. As a user interested in the intersection of science-driven innovation and equity performance, I have spent significant time analyzing how Oncopeptides AB (publ) navigates its development pipeline.
Understanding the Entity: Oncopeptides AB
Oncopeptides is a science-driven biotech company based in Stockholm, Sweden. Since its foundation in 2000, the firm has carved out a niche as a Sweden-based biotech company focusing on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. By utilizing a proprietary PDC (Peptide-Drug Conjugate) platform, they aim to address significant unmet medical needs in hematology.
For those tracking the ticker, it is important to note that Oncopeptides is a biotechnology company that is listed on Nasdaq Stockholm Small Cap under the symbol ONCO. When reviewing Oncopeptides AB stock information by Barron's or other financial portals, one observes that the company maintains a lean, The Share focused operation with approximately 75 employees, headquartered in Stockholm.
Observing Market Movements
The Oncopeptides AB (publ) stock price gained 5.38% on the last trading day, reflecting the volatility often associated with small-cap biotech entities. As a market observer, I often look at the Oncopeptides (ONCO), SE0009414576 identifiers Oncopeptides Ab (publ) Stock Forecast to ensure I am reviewing the correct instrument.
Recent data suggests ONCO is rated "Hold" with a 12-month target price of kr2.60, which presents an interesting contrast to its current trading range. Investors frequently discuss the Oncopeptides AB TR ticker, which relates to the c Oncopeptides AB, ONCO:STO summary - FT.com - Markets data ompany's capital structure and rights issues. It is worth noting that Bolaget själva uppskattar marknadpotentialen i regionen till cirka 150 MSEK, a figure that represents a significant portion of their current market valuation.
Transparency and Corporate Reporting
For those performing deep due diligence, the available in PDF format at Oncopeptides' web site under financial reports section is the gold standard for accuracy. As a Swedish biotech company, they maintain rigorous disclosure standards. Whether you are searching for Oncopeptides ab tr news or evaluating their latest quarterly Oncopeptides (ONCO) aktie - Nordnet performance, the official investor relations portal is the most reliable source.
If you have specific inquiries regarding their operations, the company provides clear contact hours (weekdays 08.00-18.00) for stakeholders. As a pharmaceutical company operating in a high-stakes environment, Oncopeptides develops cancer therapies that are monitored closely by institutional analysts.
Final Review Perspective
My experience tracking this firm has shown that Oncopeptides AB is a company that engages in the research, development, and commercialization of targeted therapies with a very specific, technical appr Oncopeptides develops cancer therapies based on proprietary technology. We focus on diseases with significant unmet medical need, advancing science from. oach. While the stock price fluctuations—such as the recent movement—can be dramatic, the underlying activity remains focused on the PDC platform.
Whether you are looking into Oncopeptide Oncopeptides AB s AB (publ) for its technical potential or its role in the Swedish biotech ecosystem, always verify the latest figures, as Oncopeptides's market position can shift rapidly based on clinical milestones and financial reports. Always remember that, as with any equity, the market for Oncopeptides AB carries risks, and maintaining a broad view of their pipeline alongside their financial statements is the best way to stay informed.